ArticleBreast cancer research and treatment2016

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Jennifer L Dine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.